Indian J Pharm Close
 

Figure 2: Improvement in severity of symptoms in Group A, B, and C. Group A: topical treatment (betamethasone valerate and [vlobetasol propionate + salicylic acid]): (a) baseline (before) and (b) 6 months (after). Group B: methotrexate + topical treatment (betamethasone valerate and [clobetasol propionate + salicylic acid]): (c) baseline (before) and (d) 6 months (after). Group C: cyclosporine + topical treatment (betamethasone valerate and [clobetasol propionate + salicylic acid]): (e) baseline (before) and (f) 6 months (after)

Figure 2: Improvement in severity of symptoms in Group A, B, and C. Group A: topical treatment (betamethasone valerate and [vlobetasol propionate + salicylic acid]): (a) baseline (before) and (b) 6 months (after). Group B: methotrexate + topical treatment (betamethasone valerate and [clobetasol propionate + salicylic acid]): (c) baseline (before) and (d) 6 months (after). Group C: cyclosporine + topical treatment (betamethasone valerate and [clobetasol propionate + salicylic acid]): (e) baseline (before) and (f) 6 months (after)